TY - JOUR
T1 - Therapeutic potential of thymoquinone and its nanoformulations in pulmonary injury
T2 - A comprehensive review
AU - Al-Gabri, Naif A.
AU - Saghir, Sultan A.M.
AU - Al-Hashedi, Sallah A.
AU - El-Far, Ali H.
AU - Khafaga, Asmaa F.
AU - Swelum, Ayman A.
AU - Al-Wajeeh, Abdullah S.
AU - Mousa, Shaker A.
AU - El-Hack, Mohamed E.Abd
AU - Naiel, Mohammed A.E.
AU - El-Tarabily, Khaled A.
N1 - Funding Information:
The authors are grateful for support from their respected universities and institutes. K.A. El-Tarabily would like to thank the library at Murdoch University, Australia for the valuable online resources and comprehensive databases.
Funding Information:
This project was funded by Abu Dhabi Research Award (AARE2019) for Research Excellence-Department of Education and Knowledge (ADEK-007; Grant #: 21S105) to Prof. Khaled El-Tarabily.
Publisher Copyright:
© 2021 Al-Gabri et al.
PY - 2021
Y1 - 2021
N2 - As a crucial organ, the lung is exposed to various harmful agents that may induce inflammation and oxidative stress, which may cause chronic or acute lung injury. Nigella sativa, also known as black seed, has been widely used to treat various diseases and is one of the most extensively researched medicinal plants. Thymoquinone (TQ) is the main component of black seed volatile oil and has been proven to have antioxidant, anti-inflammatory, and antineoplastic properties. The potential therapeutic properties of TQ against various pulmonary disorders have been studied in both in vitro and in vivo studies. Furthermore, the application of nanotechnology may increase drug solubility, cellular absorption, drug release (sustained or control), and drug delivery to lung tissue target sites. As a result, fabricating TQ as nanoparticles (NPs) is a potential therapeutic approach against a variety of lung diseases. In this current review, we summarize recent findings on the efficacy of TQ and its nanotypes in lung disorders caused by immunocompromised conditions such as cancer, diabetes, gastric ulcers, and other neurodegenerative diseases. It is concluded that TQ nanoparticles with antiinflammatory, antioxidant, antiasthma, and antitumor activity may be safely applied to treat lung disorders. However, more research is required before TQ nanoparticles can be used as pharmaceutical preparations in human studies.
AB - As a crucial organ, the lung is exposed to various harmful agents that may induce inflammation and oxidative stress, which may cause chronic or acute lung injury. Nigella sativa, also known as black seed, has been widely used to treat various diseases and is one of the most extensively researched medicinal plants. Thymoquinone (TQ) is the main component of black seed volatile oil and has been proven to have antioxidant, anti-inflammatory, and antineoplastic properties. The potential therapeutic properties of TQ against various pulmonary disorders have been studied in both in vitro and in vivo studies. Furthermore, the application of nanotechnology may increase drug solubility, cellular absorption, drug release (sustained or control), and drug delivery to lung tissue target sites. As a result, fabricating TQ as nanoparticles (NPs) is a potential therapeutic approach against a variety of lung diseases. In this current review, we summarize recent findings on the efficacy of TQ and its nanotypes in lung disorders caused by immunocompromised conditions such as cancer, diabetes, gastric ulcers, and other neurodegenerative diseases. It is concluded that TQ nanoparticles with antiinflammatory, antioxidant, antiasthma, and antitumor activity may be safely applied to treat lung disorders. However, more research is required before TQ nanoparticles can be used as pharmaceutical preparations in human studies.
KW - Anticancer activity
KW - Antimicrobial activity
KW - Bioavailability
KW - Drug delivery
KW - Lung disease
KW - Molecular potential
KW - Nanoparticle
KW - Thymoquinone
UR - http://www.scopus.com/inward/record.url?scp=85111782384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111782384&partnerID=8YFLogxK
U2 - 10.2147/IJN.S314321
DO - 10.2147/IJN.S314321
M3 - Review article
C2 - 34349511
AN - SCOPUS:85111782384
SN - 1176-9114
VL - 16
SP - 5117
EP - 5131
JO - International Journal of Nanomedicine
JF - International Journal of Nanomedicine
ER -